DesignMedix, Inc. is a drug development company focused on overcoming drug resistance, one of the major challenges impacting human health and drug development today.  The DesignMedix approach offers both a mechanism to overcome resistance, and the ability to develop an ongoing series of novel drugs.  DesignMedix has designed and synthesized a library of novel candidate drugs called reverse chloroquines (or RCQ’s) to combat several important infectious diseases.  In the companies most advance drug development program, lead compounds have been shown to overcome malaria drug resistance in human red blood cells in vitro, and to provide a cure in animal models. Work on overcoming drug resistance in other diseases is ongoing.

DesignMedix partners with leading researchers, institutions and companies to bring its products through the drug development process.   Malaria is one of the most devastating global health problems of our time responsible for about one million deaths each year. Classic drugs such as chloroquine (CQ), the main line of defense against malaria for decades, are dramatically less effective because of the emergence of drug-resistant strains of the parasites. Signs of resistance already are starting to show up for more recent drugs such as artemisinin.  There will be an ongoing need for novel malaria drugs as resistance continues to develop to new therapies.